Oncogenic KRAS in PDA can enhance mitochondrial succinate and fumarate production but also increases the resistance of the mitochondrial pool to MOMP by relying on oxidative phosphorylation for energy production, promoting its oncogenic program37. The gene discussed is KRAS; the disease is Patent ductus arteriosus.